Bio-Rad Labs (BIO) Tops Q1 EPS by 11c

Bio-Rad Labs (NYSE: BIO) reported Q1 EPS of $0.41, $0.11 better than the analyst estimate of $0.30. Revenue for the quarter came in at $500.1 million versus the consensus estimate of $477.83 million.

Guidance:

"For the full year 2017, the Company continues to anticipate currency neutral revenue growth of approximately 4 percent and improved profitability with a currency neutral operating margin target of 7 percent. This current estimate does not include the impacts of the recent acquisition of RainDance. Management will discuss this outlook in greater detail on the first-quarter 2017 financial results conference call."

For earnings history and earnings-related data on Bio-Rad Labs (BIO) click here.

You May Also Be Interested In

• BofA lists top 5 themes driving next $1tn in incremental semi sales
• AMC Entertainment prices $200M stock offering to redeem senior notes
• Amylyx ALS drug shows no serious adverse events in Phase 1 trial